The U.S. Food and Drug Administration (FDA) granted a supplemental efficacy approval for Synjardy XR (empagliflozin, metformin hydrochloride) on March 7, 2025. This approval indicates an expansion of the drug's demonstrated clinical benefits, providing updated or new efficacy data for the fixed-dose combination therapy.
Background
Synjardy XR combines two active pharmaceutical ingredients: empagliflozin and metformin hydrochloride. This combination therapy is primarily used for the management of type 2 diabetes mellitus.
Empagliflozin is an SGLT2 (sodium-glucose co-transporter 2) inhibitor. This class of drugs works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and, consequently, improved glycemic control. Beyond its role in lowering blood glucose, empagliflozin (marketed as Jardiance) has also demonstrated significant cardiovascular and renal benefits. It is approved for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, and for reducing the risk of kidney disease progression, cardiovascular death, and hospitalization in adults with chronic kidney disease.
Metformin hydrochloride is a biguanide, a widely used first-line medication for type 2 diabetes. Its primary mechanisms of action include decreasing hepatic glucose production, reducing intestinal absorption of glucose, and improving insulin sensitivity by enhancing peripheral glucose uptake and utilization.
The combination in Synjardy XR is designed to leverage the complementary mechanisms of action of both drugs to achieve comprehensive glycemic management. Prior to this supplemental approval, Synjardy XR was approved for the treatment of type 2 diabetes mellitus. This supplemental efficacy approval suggests new data supporting additional or refined benefits of this combination therapy.
What this means
This supplemental efficacy approval for Synjardy XR signifies that new clinical data supports an expanded or refined understanding of the benefits of the combined empagliflozin and metformin hydrochloride therapy. While the specific details of the expanded efficacy are not provided in the approval notice, such approvals typically relate to a new indication, an expanded patient population, or a stronger evidence base for existing claims.
For clinicians, this means a potentially broader application for Synjardy XR in managing type 2 diabetes. This could include its use in patients with specific comorbidities or characteristics, or it may offer new evidence for its role in preventing certain outcomes. This development provides additional evidence-based options for optimizing treatment strategies for patients with type 2 diabetes.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) on March 7, 2025. The details are publicly available on the FDA's website, accessdata.fda.gov, under application number NDA208658.